Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Hcv vaccine"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Aleman, Fernando, Tzarum, Netanel, Kong, Leopold, Nagy, Kenna, Zhu, Jiang, Wilson, Ian A., Law, Mansun
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 2018 Jul . 115(29), 7569-7574.
Externí odkaz:
https://www.jstor.org/stable/26510979
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
S Hekmat, MM Aslani, M Shafiee Ardestani, MR Aghasadeghi, SD Siadat, SM Sadat, M Mahdavi, S Shahbazi, F Asgarhalvaee, SMM Ghahari, F Tohidi
Publikováno v:
Vaccine Research, Vol 4, Iss 1, Pp 13-18 (2017)
Introduction: Hepatitis C virus (HCV) is one of the most serious causes of cirrhosis, liver cancer and ultimately death, worldwide. The new direct-acting drugs are not accessible for many patients around the world and progress toward new therapeutic
Externí odkaz:
https://doaj.org/article/542358c7449b488f8fd6f23d92eb50f5
Autor:
Olga V. Masalova, Ekaterina I. Lesnova, Regina R. Klimova, Ekaterina D. Momotyuk, Vyacheslav V. Kozlov, Alla M. Ivanova, Olga V. Payushina, Nina N. Butorina, Natalia F. Zakirova, Alexander N. Narovlyansky, Alexander V. Pronin, Alexander V. Ivanov, Alla A. Kushch
Publikováno v:
Vaccines, Vol 8, Iss 1, p 62 (2020)
Hepatitis C virus (HCV) is one of the major causes of chronic liver disease and leads to cirrhosis and hepatocarcinoma. Despite extensive research, there is still no vaccine against HCV. In order to induce an immune response in DBA/2J mice against HC
Externí odkaz:
https://doaj.org/article/c2e42a4645a44ad2b9c1ab170f980639
Publikováno v:
New England Journal of Medicine. 385:1235-1240
Controlled Human Infection Model — Fast Track to HCV Vaccine? The moratorium on experimentation with chimpanzees has impeded the progress of research on a vaccine against hepatitis C virus. Given t...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be5ea4c1b0f8b2b9e792164852c8acd1
https://doi.org/10.1056/nejmsb2109093
https://doi.org/10.1056/nejmsb2109093
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Olga V. Masalova, Ekaterina I. Lesnova, Vladimir A. Kalsin, Regina R. Klimova, Natalya E. Fedorova, Vyacheslav V. Kozlov, Natalya A. Demidova, Kirill I. Yurlov, Mikhail A. Konoplyannikov, Tatyana N. Nikolaeva, Alexander V. Pronin, Vladimir P. Baklaushev, Alla A. Kushch
Publikováno v:
Biology; Volume 12; Issue 6; Pages: 792
Hepatitis C virus (HCV) is one of the basic culprits behind chronic liver disease, which may result in cirrhosis and hepatocarcinoma. In spite of the extensive research conducted, a vaccine against HCV has not been yet created. We have obtained human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a429334f3f6871f70454950d2f12ec87
https://doi.org/10.3390/biology12060792
https://doi.org/10.3390/biology12060792
Autor:
Anne Finne Pihl, Shan Feng, Anna Offersgaard, Garazi Peña Alzua, Elias Honerød Augestad, Christian Kjaerulff Mathiesen, Tanja Bertelsen Jensen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jan Pravsgaard Christensen, Jens Bukh, Judith Margarete Gottwein
Publikováno v:
Pihl, A F, Feng, S, Offersgaard, A, Alzua, G P, Augestad, E H, Mathiesen, C K, Jensen, T B, Krarup, H, Law, M, Prentoe, J, Christensen, J P, Bukh, J & Gottwein, J M 2022, ' Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice ', Journal of Hepatology, vol. 76, no. 5, pp. 1051-1061 . https://doi.org/10.1016/j.jhep.2021.12.026
Background & Aims: A prophylactic vaccine is required to eliminate HCV as a global public health threat. We developed whole virus inactivated HCV vaccine candidates employing a licensed adjuvant. Further, we investigated the effects of HCV envelope p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d694e85b00eb4025d035822f4ae3b68e
https://vbn.aau.dk/ws/files/475854904/Pihl_et_al._2022_._Inactivated_whole_hepatitis_C_virus_vaccine_employing_a_licensed_adjuvant_elicits_cross_genotype_neutralizing_antibodies_in_mice.pdf
https://vbn.aau.dk/ws/files/475854904/Pihl_et_al._2022_._Inactivated_whole_hepatitis_C_virus_vaccine_employing_a_licensed_adjuvant_elicits_cross_genotype_neutralizing_antibodies_in_mice.pdf
Autor:
Emmanuelle Roch, Lucie Chopin, Vanessa Guérin, Elodie Beaumont, Benoit Joël Clément, Philippe Roingeard, Elsa Gomez-Escobar
Publikováno v:
Liver International. 40:1865-1871
The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B-C subviral envelope particles, which could be produced by industrial procedures adapted from those establ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a756ace1863acbc7d195bd0ad674980
https://doi.org/10.1111/liv.14541
https://doi.org/10.1111/liv.14541